Trial Profile
Pharmacokinetics And Safety Of A Single Dose Subcutaneous Or Intravenous Administration Of Tanezumab In Healthy Volunteers: An Open-Label, Non-Randomized Phase 1 Study.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary) ; Tanezumab (Primary)
- Indications Back pain; Cancer pain; Musculoskeletal pain; Neuralgia; Pain
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Pfizer
- 17 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jul 2009 Planned number of patients changed from 72 to 76 as reported by ClinicalTrials.gov.
- 06 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.